10 completed, 5 terminated, 3 withdrawn, 2 active not recruiting. 20 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 20 | Completed 10, Terminated 5, Withdrawn 3, Active not recruiting 2 |
| Phase 2 | 2 | Terminated 1, Withdrawn 1 |
Follow Progesterone Receptor Negative: new trials by email Literature Review of Progesterone Receptor Negative trials Research Report on Progesterone Receptor Negative
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer Celecoxib, Cyclophosphamide, Doxorubicin - Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8 | Phase 1 | Completed | Roswell Park Cancer Institute | 9 | 2019-12-06 | 2023-09-11 |
| Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deleted Ipilimumab, Nivolumab, Talimogene Laherparepvec - Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8 | Phase 1 | Terminated | Jonsson Comprehensive Cancer Center | 6 | 2019-07-10 | 2023-08-15 |
| Olaparib and Durvalumab in Treating Participants With Metastatic Triple Negative Breast Cancer Durvalumab, Olaparib - Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Negative | Phase 1 | Completed | OHSU Knight Cancer Institute | 3 | 2018-05-03 | 2020-11-20 |
| Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery Glembatumumab Vedotin, Ipilimumab, Laboratory Biomarker Analysis - Advanced Malignant Solid Neoplasm, Estrogen Receptor Negative | Phase 1 / Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2018-04-20 | 2018-07-18 | |
| IACS-010759 in Advanced Cancers Oxidative Phosphorylation Inhibitor IACS-010759, Pharmacodynamic Study, Pharmacokinetic Study - Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8 | Phase 1 | Completed | M.D. Anderson Cancer Center | 29 | 2017-11-13 | 2020-11-24 |
| Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction Laboratory Biomarker Analysis, Pharmacological Study, Talazoparib - Estrogen Receptor Negative, Head and Neck Squamous Cell Carcinoma | Phase 1 | Withdrawn | National Cancer Institute (NCI) | 2016-06-01 | 2017-04-24 | |
| Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer Hsp90 Inhibitor AT13387, Laboratory Biomarker Analysis, Pharmacological Study - Adult Solid Neoplasm, Estrogen Receptor Negative | Phase 1 | Withdrawn | National Cancer Institute (NCI) | 2016-03-01 | 2016-07-26 | |
| Galunisertib and Paclitaxel in Treating Patients With Metastatic Androgen Receptor Negative (AR-) Triple Negative Breast Cancer Galunisertib, Laboratory Biomarker Analysis, Paclitaxel - Estrogen Receptor Negative, HER2/Neu Negative | Phase 1 | Completed | Vanderbilt-Ingram Cancer Center | 29 | 2016-03-01 | 2023-11-22 |
| Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy Laboratory Biomarker Analysis, Modified Vaccinia Virus Ankara Vaccine Expressing p53, Pembrolizumab - Adult Solid Neoplasm, Bladder Carcinoma | Phase 1 | Active not recruiting | City of Hope Medical Center | 11 | 2015-12-28 | 2026-10-19 |
| Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer Biomarker Analysis, Enzalutamide, Pharmacological Study - Estrogen Receptor Negative, Estrogen Receptor Positive | Phase 1 / Phase 2 | Terminated | Vanderbilt-Ingram Cancer Center | 30 | 2015-06-01 | 2022-08-22 |
| mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian Capivasertib, Laboratory Biomarker Analysis, Olaparib - BRCA1 Mutation Carrier, BRCA2 Mutation Carrier | Phase 1 | Active not recruiting | M.D. Anderson Cancer Center | 159 | 2014-11-11 | 2026-09-04 |
| Viral Therapy In Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Cancer or Metastatic Breast Cancer Laboratory Biomarker Analysis, Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter - Estrogen Receptor Negative, Estrogen Receptor Positive | Phase 1 | Completed | Mayo Clinic | 12 | 2013-04-09 | 2023-02-14 |
| Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast Cancer Dinaciclib, Epirubicin Hydrochloride, Laboratory Biomarker Analysis - Estrogen Receptor Negative, HER2/Neu Negative | Phase 1 | Completed | National Cancer Institute (NCI) | 40 | 2012-08-21 | 2018-03-30 |
| Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors Carboplatin, Laboratory Biomarker Analysis, Paclitaxel - Adult Solid Neoplasm, Estrogen Receptor Negative | Phase 1 | Completed | National Cancer Institute (NCI) | 22 | 2011-01-01 | 2015-05-25 |
| Lapatinib Ditosylate and Akt Inhibitor MK2206 in Treating Women With Metastatic Breast Cancer Akt Inhibitor MK2206, Laboratory Biomarker Analysis, Lapatinib Ditosylate - Estrogen Receptor Negative, Estrogen Receptor Positive | Phase 1 | Terminated | National Cancer Institute (NCI) | 4 | 2011-01-01 | 2015-08-27 |
| Weekly Doses of Cilengitide and Paclitaxel in Treating Patients With Advanced Solid Tumors That Cannot Be Removed by Surgery Cilengitide, Laboratory Biomarker Analysis, Paclitaxel - Adult Solid Neoplasm, Estrogen Receptor Negative | Phase 1 | Completed | National Cancer Institute (NCI) | 13 | 2010-12-01 | 2016-03-15 |
| Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097, Paclitaxel, and Carboplatin Before Surgery in Treating Patients With Stage II or Stage III Triple-Negative Breast Cancer Carboplatin, Gamma-Secretase Inhibitor RO4929097, Laboratory Biomarker Analysis - Estrogen Receptor Negative, HER2/Neu Negative | Phase 1 | Terminated | National Cancer Institute (NCI) | 14 | 2010-12-01 | 2015-09-04 |
| Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer Laboratory Biomarker Analysis, Pegylated Liposomal Doxorubicin Hydrochloride, Pharmacological Study - Estrogen Receptor Negative, HER2/Neu Negative | Phase 1 | Completed | National Cancer Institute (NCI) | 45 | 2010-06-01 | 2017-12-22 |
| RO4929097 and Vismodegib in Treating Patients With Breast Cancer That is Metastatic or Cannot Be Removed By Surgery Gamma-Secretase Inhibitor RO4929097, Laboratory Biomarker Analysis, Pharmacogenomic Study - Estrogen Receptor Negative, HER2/Neu Negative | Phase 1 | Terminated | National Cancer Institute (NCI) | 13 | 2009-11-01 | 2015-04-15 |
| Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy Laboratory Biomarker Analysis, Pharmacological Study, Veliparib - Basal-Like Breast Carcinoma, BRCA1 Mutation Carrier | Phase 1 | Completed | National Cancer Institute (NCI) | 98 | 2009-04-20 | 2018-06-29 |
Triple Negative Breast Neoplasms (19) · Breast Neoplasms (15) · Ovarian Neoplasms (5) · Breast Neoplasms, Male (4) · Fallopian Tube Neoplasms (4) · Pancreatic Neoplasms (3) · Squamous Cell Carcinoma of Head and Neck (3) · Breast Carcinoma In Situ (2) · Carcinoma, Non-Small-Cell Lung (2) · Melanoma (2) · Neoplasm Metastasis (2) · Carcinoma, Hepatocellular (1) · Carcinoma, Renal Cell (1) · Colonic Neoplasms (1) · Hereditary Breast and Ovarian Cancer Syndrome (1)
Breast Diseases (20) · Neoplasms (20) · Neoplasms by Site (20) · Skin Diseases (20) · Skin and Connective Tissue Diseases (20) · Endocrine Gland Neoplasms (7) · Endocrine System Diseases (7) · Neoplasms by Histologic Type (7) · Female Urogenital Diseases (6) · Female Urogenital Diseases and Pregnancy Complications (6) · Urogenital Diseases (6) · Urogenital Neoplasms (6) · Adnexal Diseases (5) · Breast Neoplasms (5) · Carcinoma (5)
Paclitaxel (5) · Taxes (5) · veliparib (3) · 2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide (2) · CTLA-4 Antigen (2) · Carboplatin (2) · Doxorubicin (2) · Ipilimumab (2) · Nivolumab (2) · Pharmacogenomic Testing (2) · olaparib (2) · talazoparib (2) · (2,4-dihydroxy-5-isopropylphenyl)-(5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl)methanone (1) · 2-(3-(2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo(f)imidazo(1,2-d)(1,4)oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanamide (1) · CR011-vcMMAE (1)
National Cancer Institute (NCI) (11) · M.D. Anderson Cancer Center (2) · Vanderbilt-Ingram Cancer Center (2) · City of Hope Medical Center (1) · Jonsson Comprehensive Cancer Center (1) · Mayo Clinic (1) · OHSU Knight Cancer Institute (1) · Roswell Park Cancer Institute (1)
United States (17)
Patricia LoRusso (2) · Shannon Puhalla (2) · Vandana Abramson, MD (2) · Bhavana Pothuri (1) · Daniel Renouf (1) · Ewa Mrozek (1) · Haeseong Park (1) · John A Glaspy (1) · Julian Molina (1) · Panagiotis Konstantinopoulos (1) · Scott Okuno (1) · Shannon N Westin (1) · Shipra Gandhi (1) · Stacy Moulder (1) · Timothy A Yap (1)
PMID 32379297, PMID 25947565, PMID 36658425, PMID 37621406
P30CA016672 (2), P30CA022453 (2), P30CA047904 (2), P30CA068485 (2), U01CA062487 (2), U01CA099168 (2), N01CM62204 (1), P30CA006516 (1), P30CA013330 (1), P30CA015083 (1), P30CA016058 (1), P50CA083639 (1), R01CA152228 (1), U01CA062461 (1), U01CA062490 (1)